VIRACTA THERAPEUTICS
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
VIRACTA THERAPEUTICS
Industry:
Biopharma Biotechnology Medical Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Cardiff By The Sea, California, United States
Country:
United States
Website Url:
http://www.viracta.com
Total Employee:
11+
Status:
Active
Contact:
(858)400-8470
Email Addresses:
[email protected]
Total Funding:
194.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Apache Wordpress Plugins
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2020-11-30 | Sunesis Pharmaceuticals | Sunesis Pharmaceuticals acquired by Viracta Therapeutics | N/A |
Investors List
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Viracta Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Viracta Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Post-IPO Equity - Viracta Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Viracta Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Viracta Therapeutics
LifeSci Venture Partners
LifeSci Venture Partners investment in Post-IPO Equity - Viracta Therapeutics
aMoon Fund
aMoon Fund investment in Post-IPO Equity - Viracta Therapeutics
Sectoral Asset Management
Sectoral Asset Management investment in Post-IPO Equity - Viracta Therapeutics
Ridgeback Capital
Ridgeback Capital investment in Post-IPO Equity - Viracta Therapeutics
BVF Partners
BVF Partners investment in Post-IPO Equity - Viracta Therapeutics
Key Employee Changes
Date | New article |
---|---|
2020-03-25 | Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer |
Official Site Inspections
http://www.viracta.com Semrush global rank: 3.25 M Semrush visits lastest month: 5.08 K
- Host name: r200.websiteservername.com
- IP address: 204.44.192.14
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto